Extera Partners
- Company typePrivate
- Founded2007
- HeadquartersCambridge, United States
- Headcount11–50
- GTM typeB2B
- OfferingServices
Extera Partners firmographics
Firmographics- Name
- Extera Partners
- Legal name
- Extera Partners LLC
- Website
- https://exterapartners.com
- Company type
- Private
- Founded year
- 2007
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Extera Partners industry classification
Industry- Product category
- Life Science Venture Capital & Corporate Development Advisory
- NAICS
- Portfolio Management and Investment Advice (52394)
- SIC
- Investment Advice (6282)
- akta.pro primary industry
- Healthcare & Life Sciences Growth Equity (FSANACAB)
- akta.pro secondary industry
- Sector-Focused Venture Capital (Vertical Specialists) (FSANAAAD)
Keywords
Where Extera Partners is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Extera Partners business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Others
Revenue model
- Venture Creation & Investment Returns: Extera Partners invests in existing life science companies and builds new ones, generating financial returns for investors through strategic transactions and public listings. Revenue is derived from investment returns and advisory fees from corporate development services.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels1 record
Extera Partners product offering
Product offeringCore offering
Extera Partners invests in existing life science companies and builds new biotechnology and medical device ventures by leveraging unique deal flow, a team of industry leaders, internal financing resources, and a close network of family offices and institutional investors. The firm also provides corporate development advisory services including transaction management, strategic planning, and business development support for life science companies. Since inception in 2007, Extera has generated substantial financial returns for investors through strategic transactions and public listings.
Product overview
Extera Partners operates as a single unified offering focused on life science venture creation and corporate development services. The company invests in existing life science companies and builds new ventures by leveraging unique deal flow, industry leadership, financing resources, and a network of family offices and institutional investors. Their core services include corporate development advisory and venture creation, with a focus on biotechnology and medical device ventures aimed at improving clinical outcomes, enhancing quality of life, and reducing healthcare costs. Since inception in 2007 as a corporate development advisory firm, they have generated financial returns through strategic transactions and public listings.
Differentiator
Problem solved
Functional benefit
Products and services
- Corporate Development Services Strategic advisory services for corporate development including transaction management, strategic planning, and business development support, targeted at life science companies.
- Life Science Venture Creation & Investments Investment in and creation of new biotechnology and medical device ventures aimed at improving clinical outcomes, enhancing quality of life, and reducing healthcare costs. Available to investors and life science founders through Extera's network of family offices and institutional investors.
Companies that use Extera Partners
Customer profileNamed customers6 records
Segments3 records
Ideal customer profiles2 records
Extera Partners technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Extera Partners partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- BioAssets Development Corporation (BDC)minorExtera served as advisor to BDC on option-to-acquisition transaction with Cephalon. Cephalon paid $30M upfront for option, with BDC shareholders receiving additional milestone payments. Transaction closed October 2010 with Cephalon acquiring BDC for $12.5M.
Scale indicators2 records
Recent moves6 records
Expansion highlights4 records
Extera Partners competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Extera Partners social profiles
Digital presenceExtera Partners financial estimates
Financial estimateRevenue estimate
Valuation estimate
Extera Partners leadership team
Management profileNumber of profiles
Profiles11 records
Extera Partners funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Extera Partners M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Extera Partners
What does Extera Partners do?
Extera Partners invests in existing life science companies and builds new biotechnology and medical device ventures by leveraging unique deal flow, a team of industry leaders, internal financing resources, and a close network of family offices and institutional investors. The firm also provides corporate development advisory services including transaction management, strategic planning, and business development support for life science companies. Since inception in 2007, Extera has generated substantial financial returns for investors through strategic transactions and public listings.
Is Extera Partners a public or private company?
Extera Partners is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Extera Partners founded?
Extera Partners was founded in 2007. It employs 11 to 50 people.
Where is Extera Partners based?
Extera Partners is headquartered in Cambridge, United States, in the North America region.
How does Extera Partners make money?
One revenue line is on record: venture Creation & Investment Returns.
Does Extera Partners have an API?
No public API is recorded for Extera Partners.
What industry is Extera Partners in?
Extera Partners's product category is Life Science Venture Capital & Corporate Development Advisory. Its primary akta.pro industry code is FSANACAB, Healthcare & Life Sciences Growth Equity, with a secondary code of FSANAAAD, Sector-Focused Venture Capital (Vertical Specialists). Its NAICS code is 52394 and its SIC code is 6282.